Matrix Biology of Abdominal Aortic Aneurysms in Diabetes: Mechanisms Underlying the Negative Association

REFERENCES

• Lederle F. A., Johnson G. R., Wilson S. E., Chute E. P., Litooy F. N., Bandyk D., Krupski W. C., Barone G. W., Acher C. W., Ballard D. J. Prevalence and associations of abdominal aortic aneurysm detected through screening. Ann. Int. Med. 1997; 126: 441–449
   PubMed Web of Science ®Google Scholar
• Blanchard J. F. Epidemiology of abdominal aortic aneurysms. Epidemiol. Rev. 1999; 21: 207–221
   PubMed Web of Science ®Google Scholar
• Jamrozik K., Norman P. E., Spencer C. A., Parsons R. W., Tuohy R., Lawrence-Brown M. M., Dickinson J. A. Screening for abdominal aortic aneurysms: lessons from a population-based study. Med. J. Aust. 2000; 173: 345–350
   PubMed Web of Science ®Google Scholar
• Shteinberg D., Halak M., Shapiro S., Kinarty A., Sobol E., Lahat N., Karmeli R. Abdominal aortic aneurysm and aortic occlusive disaese: a comparison of risk factors and inflammatory response. Eur. J. Vasc. Endovas. Surg. 2000; 20: 462–465
   PubMed Web of Science ®Google Scholar
• Blanchard J., Armenian H., Friesen P. Risk factors for abdominal aortic aneurysm: results of a case-control study. Am. J. Epidemiol. 2000; 151: 575–583
   PubMed Web of Science ®Google Scholar
• Marian A. On genetics, inflammation, and abdominal aortic aneurysm. Circulation 2001; 103: 2222–2224
   PubMed Web of Science ®Google Scholar
• Eriksson P., Jormsjo-Pettersson S., Brady A., Deguchi H., Hamsten A., Powell J. Genotype-phenotype relationships in an investigation of the role of proteases in abdominal aortic aneurysm expansion. Br. J. Surg. 2005; 92: 1372–1276
   PubMed Web of Science ®Google Scholar
• LaMorte W. W., Scott T. E., Menzoian J. O. Racial differences in the incidence of femoral bypass and abdominal aortic aneurysmectomy in Massachusetts: relationship to cardiovascular risk factors. J. Vasc. Surg. 1995; 21: 422–431
   PubMed Web of Science ®Google Scholar
• Mattes E., Davis T. M.E., Yang D., Ridley D., Lund H., Norman P. E. Prevalence of abdominal aortic aneurysms in men with diabetes. M.J.A. 1997; 166: 630–634
   Web of Science ®Google Scholar
• Brady A. R., Thompson S. G., Fowkes G. R., Greenhalgh R. M., Powell J. T. Abdominal aortic aneurysm expansion. Risk factors and time intervals for surveillance. Circulation 2004; 110: 16–21
   PubMed Web of Science ®Google Scholar
• Norman P. E., Spencer C. A., Lawrence-Brown M. M., Jamrozik K. C-reactive protein levels and the expansion of screen-detected abdominal aortic aneurysms in men. Circulation 2004; 110: 862–866
   PubMed Web of Science ®Google Scholar
• Le M. T.Q., Jamrozik K., Davis T. M.E., Norman P. Negative association between infra-renal aortic diameter and glycaemia: the health in men study. Eur. J. Vasc. Endovasc. Surg. 2007; 33: 592–598
   PubMed Web of Science ®Google Scholar
• Sakalihasan N., Heyeres A., Nusgens B. V., Limet R., Lapiere C. M. Modifications of the extracellular matrix of aneurysmal abdominal aortas as a function of their size. Eur. J. Vasc. Surg. 1993; 7: 633–637
   PubMedGoogle Scholar
• Freestone T., Turner R. J., Coady A., Higman D. J., Greenhalgh R. M., Powell J. T. Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler. Thromb. Vasc. Biol. 1995; 15: 1145–1151
   PubMed Web of Science ®Google Scholar
• Carrell T. W.G., Burnand K. G., Wells G. M.A., Clements J. M., Smith A. Stromelysin-1 (matrix metalloproteinase-3). and tissue inhibitor of metalloproteinase-3 are overexpressed in the wall of abdominal aortic aneurysms. Circulation 2002; 105: 477–482
   PubMed Web of Science ®Google Scholar
• Curci J. A., Liao S., Huffman M. D., Shapiro S. D., Thompson R. W. Expression and localisation of macrophage elastase (matrix metalloproteinase-12) in abdominal aortic aneurysms. J. Clin. Invest. 1998; 102: 1900–1910
   PubMed Web of Science ®Google Scholar
• Thompson R. W., Holmes D. R., Mertens R. A., Liao S., Botney M. D., Mecham R. P., Welgus H. G., Parks W. C. Production and localisation of 92-kilodalton gelatinase in abdominal aortic aneurysms. J. Clin. Invest. 1995; 96: 318–326
   PubMed Web of Science ®Google Scholar
• Sakalihasan N., Delvenne P., Nusgens B. V., Limet R., Lapiere C. M. Activated forms of MMP2 and MMP9 in abdominal aortic aneurysms. J. Vasc. Surg. 1996; 24: 127–133
   PubMed Web of Science ®Google Scholar
• Goodall S., Crowther M., Hemingway D. M., Bell P. R., Thompson M. M. Ubiquitous elevation of matrix metalloproteinase-2 expression in the vasculature of patients with abdominal aneurysms. Circulation. 2001; 104: 304–309
   PubMed Web of Science ®Google Scholar
• McMillan W. D., Tamarina N. T., Cipollone M., Jonson D. A., Parker M. A., Pearce W. H. Size matters: the relationship between MMP-9 expression and aortic diameter. Circulation 1997; 96: 2228–2232
   PubMed Web of Science ®Google Scholar
• Pyo R., Lee J. K., Shipley J. M., Curci J. A., Mao D., Ziporin S. J., Ennis T. L., et al. Targeted gene disruption of metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J. Clin. Invest. 2000; 105: 1641–1649
   PubMed Web of Science ®Google Scholar
• Longo G. M., Xiong W., Greiner T. C., Zhao Y., Fiotti N., Baxter B. T. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J. Clin. Invest. 2002; 110: 625–632
   PubMed Web of Science ®Google Scholar
• Pearce W. H., Shively V. P. Abdominal aortic aneurysm as a complex multifactorial disease. Interactions of polymorphisms of inflammatory genes, features of autoimmunity, and current status of MMPs. Ann. NY Acad. Sci. 2006; 1085: 117–132
   PubMed Web of Science ®Google Scholar
• van Vlijmen-van Keulen C. J., Vahl A. C., Hennekam R. C.M., Rauwerda J. A., Pals G. Genetic linkage of candidate genes in families with abdominal aortic aneurysms?. Eur. J. Vasc. Endovas. Surg. 2003; 26: 205–210
   PubMed Web of Science ®Google Scholar
• Jones G. T., Phillips L. V., Harris E. L., Rossaak J. I., van Rij A. M. A functional matrix metalloproteinase 9 polymorphism (C-1562T). is associated with abdominal aortic aneurysm. J. Vasc. Surg. 2003; 38: 1363–1367
   PubMed Web of Science ®Google Scholar
• Jormsjo S., Ye S., Moritz J., Walter D. H., Dimmeler S., Zeiher A. M., Henney A., Hamsten A., Eriksson P. Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. Circ. Res. 2000; 86: 998–1003
   PubMed Web of Science ®Google Scholar
• Mauer S. Structural-functional correlations of diabetic nephropathy. Kidney Int. 1994; 45: 612–622
   PubMed Web of Science ®Google Scholar
• Jones S. C., Saunders H. J., Pollock C. A. High glucose increases growth and collagen synthesis in cultured human tubulointerstitial cells. Diabetic Med. 1999; 16: 932–938
   PubMed Web of Science ®Google Scholar
• Lam S., Verhagen N. A.M., Strutz F., van der Pijl J. W., Daha M. R., van Kooten C. Glucose-induced fibronectin and collagen type III expression in renal fibroblasts can occur independent of TGF-β1. Kidney Int. 2003; 63: 878–888
   PubMed Web of Science ®Google Scholar
• Asbun J., Manso A. M., Villareal F. J. Profibrotic influence of high glucose concentration on cardiac fibroblast functions: effects of losartan and vitamin E. Am. J. Physiol. (Endocinol. Met.) 2005; 288: H227–H234
   PubMed Web of Science ®Google Scholar
• Singh R., Alavi N., Singh A. K., Leehey D. Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes 1999; 48: 2066–2073
   PubMed Web of Science ®Google Scholar
• Murphy M., Godson C., Cannon S., Kato S., Mackenzie H. S., Martin F., Brady H. R. Suppression subtraction hybridization identiefies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J. Biol. Chem. 1999; 274: 5830–5834
   PubMed Web of Science ®Google Scholar
• Twigg S. M., Chen M. M., Joly A. H., Chakrapani S. D., Tsubaki J., Kinm H.-S., Oh Y., Rosenfeld R. G. Advanced blycosylation end products up-regulate connective tissue growth factor (insulin-like growth factor-binding protein-related protein-2). in human fibroblasts: a potential mechanism for expansion of extracellular matrix in diabetes mellitus. Endocinology 2001; 142: 1760–1769
   PubMed Web of Science ®Google Scholar
• McLennan S., Wang X., Moreno V., Yue D., Twigg S. Connective tissue growth factor mediates high glucose effects on matrix degradation through tissue inhibitor of matrix metalloproteinase type 1: implications for diabetic nephropathy. Endocrinology 2004; 145: 5646–5655
   PubMed Web of Science ®Google Scholar
• Death A., Fisher E., McGrath K., Yue D. High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis. 2003; 168: 263–269
   PubMed Web of Science ®Google Scholar
• Uemura S., Matsushita H., Li W., Glassford A. J., Asagami T., Lee K.-H., Harrison D. G., Tsao P. S. Diabetes mellitus enhances vascular matrix metalloproteinase activity. Role of oxidative stress. Circ. Res. 2001; 88: 1291–1298
   PubMed Web of Science ®Google Scholar
• Nakamura T., Fukui M., Ebihara I., Osada S., Tomino Y., Koide H. Abnormal gene expression of matrix metalloproteinases and their inhibitor in glomeruli from diabetic rats. Renal Physiol. Biochem. 1994; 17: 316–325
   PubMedGoogle Scholar
• Wu K., Setty S., Mauer S. M., Killen P., Nagase H., Michael A. F., Tsibary E. Altered kidney matrix gene expression in early stages of experimental diabetes. Acta Anatomica 1997; 158: 155–165
   PubMedGoogle Scholar
• Portik-Dobos V., Anstadt M. P., Hutchinson J., Bannan M., Ergul A. Evidence for matrix metalloproteinase induction/activation system in arterial vasculature and decreased synthesis and activity in diabetes. Diabetes 2002; 51: 3063–3068
   PubMed Web of Science ®Google Scholar
• Del Prete D., Anglani F., Forino M., Ceol M., Fioretto P., Nosadini R., Baggio B., Gambaro G. Down-regulation of glomerular matrix metalloproteinase-2 gene in human NIDDM. Diabologia 1997; 40: 1449–1454
   PubMed Web of Science ®Google Scholar
• McLennan S., Kelly D., Cox A., Cao Z., Lyons J., Yue D., Gilbert R. Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases. Diabetologia 2002; 45: 268–275
   PubMed Web of Science ®Google Scholar
• Jesmin S., Sakuma I., YHattori Y., Kitabatake A. Role of angiotensin II in altered expression of molecules responsible for coronary matrix remodeling in insulinresistant diabetic rats. Arterioscler. Thromb. Vasc. Biol. 2003; 23: 2021–2026
   PubMed Web of Science ®Google Scholar
• Daugherty A., Manning M. W., Cassis L. A. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J. Clin. Invest. 2000; 105: 1605–1612
   PubMed Web of Science ®Google Scholar
• Grant S. F., Thorleifsson G., Reynisdottir I., Benediktsson R., Manolescu A. J.S., et al. Variant of transcription factor 7-like 2 (TCF7L2). gene confers risk of type 2 diabetes. Nat. Genet. 2006; 38: 320–323
   PubMed Web of Science ®Google Scholar
• Janssens A. C.J.W., Gwinn M., Valdez R., Naravan K. M.V., Khoury M. J. Predictive genetic testing for type 2 diabetes. BMJ 2006; 333: 509–510
   PubMed Web of Science ®Google Scholar
• Shimazaki A., Kawamura Y., Kanazawa A., Sekine A., Saito S., Tsunoda T., Koya D., et al. Genetic variations in the gene encoding ELMO1 are associated with susceptibility to diabetic nephropathy. Diabetes 2005; 54: 1171–1178
   PubMed Web of Science ®Google Scholar
• Astrand H., Ryden-Ahlgren A., Sundkvist G., Sandgren T., Lanne T. Reduced aortic wall stress in diabetes mellitus. Eur. J. Vasc. Endovasc. Surg. 2007; 33: 592–598
   PubMed Web of Science ®Google Scholar
• Sonesson B., Hansen F., Stale H., Lanne T. Compliance and diameter in the human abdominal aorta—the influence of sex and age. Eur. J. Vasc. Surg. 1993; 7: 690–697
   PubMedGoogle Scholar
• Lijnen H. R. Plasmin and matrix metalloproteinases in vascular remodelling. Thromb. Haemost. 2001; 86: 324–333
   PubMed Web of Science ®Google Scholar
• Allaire E., Hasenstab D., Kenagy R. D., Starcher B., Clowes M. M., Clowes A. W. Prevention of aneurysm development and rupture by local overexpression of plasminogen activator inhibitor-1. Circulation 1998; 98: 249–255
   PubMed Web of Science ®Google Scholar
• Deng G. G., Martin-McNulty B., Sukovich D. A., Freay A., Halks-Miller M., Thinnes T., Luskutoff D. J., Carmeleit P., Dole W. P., Wang Y.-X. Urokinase-type plasminogen activator plays a critical role in angiotensin II-induced abdominal aortic aneurysm. Circ. Res. 2003; 92: 510–517
   PubMed Web of Science ®Google Scholar
• Touat Z., Ollivier V., Dai J., Huisse M.-G., Bezeaud A., Sebbag U., Palombi T., Rossignol P., Meilhac O., Guillin M.-C., Michel J.-B. Renewal of mural thrombus releases plasma markers and is involved in aortic aneurysm evolution. Am. J. Path. 2006; 168: 1022–1030
   PubMed Web of Science ®Google Scholar
• Lindholt J. S., Jorgensen B., Fasting H., Henneberg E. W. Plasma levels of plasmin-antiplasmin complexes are predictive for small andominal aortic aneurysms expanding to operation-recommendable sizes. J. Vasc. Surg. 2001; 34: 611–615
   PubMed Web of Science ®Google Scholar
• Rossaak J. I., van Rij A., Jones J. T., Harris E. L. Association of G4/G5 polymorphism in the promoter region of plasminogen activator inhibitor-1 with abdominal aortic aneurysms. J. Vasc. Surg. 2000; 31: 1026–1032
   PubMed Web of Science ®Google Scholar
• Festa A., D'Agostino R., Jr, Mykkanen L., Tracey R. P., Zaccaro D. J., Hales C. N., Haffner S. M. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. Arterioscler. Thromb. Vasc. Biol. 1999; 19: 562–568
   PubMed Web of Science ®Google Scholar
• De Cosmo S., Tassi V., Thomas S., Piras G. P., Trevisan R., Cavallo Perin P., Bacci S., Zucaro L., Cisternino C., Trischitta V., Viberti G. C. The Decorin gene 179 allelic variant is associated with a slower progression of renal disease in patients with type 1 diabetes. Nephron 2002; 92: 72–76
   PubMed Web of Science ®Google Scholar
• Funk M., Endler G., Exner M., Marculescu R., Endler L., Abrahamian H., Mauler H., Grimm A., Raith M., Mannhalter C., Prager R., Irsigler K., Wagner O. F. PAI-1 4G/5G insertion/deletion promoter polymorphism and microvascular complications in type 2 diabetes mellitus. Wien Klin Wochenschr. 2005; 117: 707–710
   PubMed Web of Science ®Google Scholar
• Winlove C. P., Parker K. H., Avery N. C., Bailey A. J. Interactions of elastin and aorta with sugars in vitro and their effects on biochemical and physical properties. Diabetologia 1996; 39: 1131–1139
   PubMed Web of Science ®Google Scholar
• Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J. Hyperten. 2003; 21: 3–12
   PubMed Web of Science ®Google Scholar
• Konova E., Baydanoff S., Atanasova M., Velkova A. Age-related changes in the glycation of human aortic elastin. Exp. Gerontol. 2004; 39: 249–254
   PubMed Web of Science ®Google Scholar
• Schram M. T., Henry R. M.A., van Dijk R. A.J.M., Kostense P. J., Dekker J. M., Nijpels G., Heine R. J., Bouter L. M., et al. Increased central artery stiffness in impaired glucose metabolism and type 2 diabetes. The Hoorn Study. Hypertension 2004; 43: 176–181
   PubMed Web of Science ®Google Scholar
• Rittie L., Berton A., Monboisse J.-C., Hornebeck W., Gillery P. Decreased contraction of glycated lattices coincides with impaired matrix metalloproteinase production. Biochem. Biophys. Res. Comm. 1999; 264: 488–492
   PubMed Web of Science ®Google Scholar
• Kuzuya M., Asai T., Kanda S., Maeda K., Cheng X., Iguchi A. Glycation cross-links inhibit matrix metalloproteinase-2 activation in vascular smooth muscle cells cultured on collagen lattice. Diabetologia 2001; 44: 433–436
   PubMed Web of Science ®Google Scholar
• Kim Y. S., Kim B. C., Song C. Y., Hong H. K., Moon K. C., Lee H. S. Advanced glycosylation end products stimulate collagen mRNA synthesis in mesangial cells mediated by protein kinase C and transforming growth factor-beta. J. Lab. Clin. Med. 2001; 138: 59–68
   PubMed Web of Science ®Google Scholar
• Anderson S., Wu K., Nagase H., Stettlet-Stevenson W., Kim Y., Tsibary E. Effect of matrix glycation on expression of Type IV collagen, MMP-2, MMP-9 and TIMP-1 by human mesangial cells. Cell Adhes. Commun. 1996; 4: 89–101
   PubMed Web of Science ®Google Scholar
• Shimizu K., Mitchell R. N., Libby P. Inflammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler. Thromb. Vasc. Biol. 2006; 26: 987–994
   PubMed Web of Science ®Google Scholar
• Fogelstrand L., Hulthe J., Hulten L. M., Wiklund O., Fagerberg B. Monocytic expression of CD14 and CD18, circulating adhesion molecules and inflammatory markers in women with diabetes mellitus and impaired glucose tolerance. Diabetologia 2004; 47: 1948–1952
   PubMed Web of Science ®Google Scholar
• Ziegler D. Type 2 diabetes as an inflammatory cardiovascular disorder. Curr. Mol. Med. 2005; 5: 309–322
   PubMed Web of Science ®Google Scholar
• Marfella R., D'Amico M., Esposito K., Baldi A., Di Filippo C., Siniscalchi M., Sasso F. C., et al. The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment. Diabetes Care 2006; 55: 622–632
   Web of Science ®Google Scholar
• Burke A. P., Kolodgie F. D., Zieske A., Fowler D. R., Weber D. K., Varghese P. J., Farb A., Virmani R. Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler. Thromb. Vasc. Biol. 2004; 24: 1266–1271
   PubMed Web of Science ®Google Scholar
• Cipollone F., Iezzi A., Fazia M., Zucchelli M., Pini B, Cuccurullo C., De Cesare D., De Blasis G., et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 2003; 108: 1070–1077
   PubMed Web of Science ®Google Scholar
• Viardot A., Grey S. T., Mackay F., Chisholm D. Potential anti-inflammatory role of insulin via the preferential polarization of effector T cells towards a T-helper 2 phenotype. Endocrinology 2007; 148: 346–353
   PubMed Web of Science ®Google Scholar
• McGrath J. C., Deighan C., Briones A. M., Shafaroudi M. M., McBride M., Adler J., Arribas S. M., Vila E., Daly C. New aspects of vascular remodelling: the involvement of all vascular cell types. Exp. Physiol. 2005; 90: 469–475
   PubMed Web of Science ®Google Scholar
• Wesley R. N., Meng X., Godin D., Galis Z. S. Extracellular matrix modulates macrophage functions characteristic to atheroma: collagen type I enhances acquisition of resident macrophage traits by human peripheral blood monocytes in vitro. Arterioscler. Thromb. Vasc. Biol. 1998; 18: 432–440
   PubMed Web of Science ®Google Scholar
• Lepidi S., Kenagy R. D., Raines E. W., Chiu E. S., Chait A., Ross R., Clowes A. W. MMP9 production by human monocyte-derived macrophages is decreased on polymerized type I collagen. J. Vasc. Surg. 2001; 34: 1111–1118
   PubMed Web of Science ®Google Scholar
• Soldatos G., Cooper M. E. Advanced glycation end products and vascular structure and function. Curr. Hypertens. Rep. 2006; 8: 472–478
   PubMed Web of Science ®Google Scholar
• Costa J., Borges M., David C., Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 2006; 332: 1115–1124
   PubMed Web of Science ®Google Scholar
• Schouten O., van Laanen J. H.H., Boersma E., et al. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur. J. Vasc. Endovasc. Surg. 2006; 32: 21–26
   PubMed Web of Science ®Google Scholar
• Lewis E. J., Hunsicker L. G., Bain R. P., Rohde R. D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N. Eng. J. Med. 1993; 329: 1456–1462
   PubMed Web of Science ®Google Scholar
• Lit Y. Z., Meyer T. Managing diabetic nephropathy: recent studies. Curr. Opin. Nephrol. Hypertens. 2006; 15: 111–116
   PubMed Web of Science ®Google Scholar
• Liao S., Miralles M., Kelley B. J., Curci J. A., Borhani M., Thompson R. W. Suppression of experimental abdominal aneurysms by treatment with angiotensin-converting enzyme inhibitors. J. Vasc. Surg. 2001; 33: 1057–1064
   PubMed Web of Science ®Google Scholar
• Hackam D. G., Thiruchelvam D., Redelmeier D. A. Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study. Lancet 2006; 368: 659–665
   PubMed Web of Science ®Google Scholar
• Rizzoni D., Porteri E., De Ciuceis C., Sleiman I., Rodella L., Rezzani R., Paiardi S., Bianchi R., Ruggeri G., Boari G. E., Muiesan M. L., Salvetti M., Zani F., Miclini M., Rosei E. A. Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus. Hypertension 2005; 45: 659–665
   PubMed Web of Science ®Google Scholar
• Jandeleit-Dahm K. A., Lassila M., Allen T. J. Advanced glycation end products in diabetes-associated atherosclerosis and renal disease: interventional studies. Ann. NY Acad. Sci. 2005; 1043: 759–766
   PubMed Web of Science ®Google Scholar
• Bakris G. L., Bank A. J., Kass D. A., Neutel J. M., Preston R. A., Oparil S. Advanced glycation end-product cross-link breakers. Am. J. Hypertens. 2004; 17: 23S–30S
   PubMed Web of Science ®Google Scholar
• Giannico G., Cortes P., Baccora M. H., Hassett C., Taube D. W., Yee J. Glibenclamide prevents increased extracellular matrix formation induced by high glucose concentration in mesangial cells. Am. J. Physiol. Renal. Physiol. 2007; 292: F57–F65
   PubMed Web of Science ®Google Scholar
• Fukui D., Miyagawa S., Soeda J., Tanaka J., Urayama H., Kawasaki S. Overexpression of transforming growth factor β1 in smooth muscle cells of human abdominal aortic aneurysm. Eur. J. Vasc. Endovas. Surg. 2003; 25: 540–545
   PubMed Web of Science ®Google Scholar
• McLennan S., Fisher E., Martell S., Death A., Williams P., Lyons J., Yue D. Effects of glucose on matrix metalloproteinase and plasmin activities in mesangial cells: possible role in diabetic nephropathy. Kidney Int. 2000; 58: S81–S87
   Web of Science ®Google Scholar
• McLennan S. V., Martell S. Y.K., Yue D. K. High glucose concentration inhibits the expression of membrane type metalloproteinase by mesangial cells: possible role in mesangium accumulation. Diabetologia 2000; 43: 642–648
   PubMed Web of Science ®Google Scholar